CA2959307C - Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof - Google Patents

Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof Download PDF

Info

Publication number
CA2959307C
CA2959307C CA2959307A CA2959307A CA2959307C CA 2959307 C CA2959307 C CA 2959307C CA 2959307 A CA2959307 A CA 2959307A CA 2959307 A CA2959307 A CA 2959307A CA 2959307 C CA2959307 C CA 2959307C
Authority
CA
Canada
Prior art keywords
levodopa
dopamine
inhibitor
carbidopa
gel composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959307A
Other languages
English (en)
French (fr)
Other versions
CA2959307A1 (en
Inventor
Roger Bolsoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INTRANCE MEDICAL SYSTEMS, INC.
Original Assignee
Intrance International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE1451034A external-priority patent/SE538425C2/en
Application filed by Intrance International AB filed Critical Intrance International AB
Priority to CA3175785A priority Critical patent/CA3175785A1/en
Publication of CA2959307A1 publication Critical patent/CA2959307A1/en
Application granted granted Critical
Publication of CA2959307C publication Critical patent/CA2959307C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2959307A 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof Active CA2959307C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3175785A CA3175785A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1451034-1 2014-09-04
SE1451034A SE538425C2 (en) 2014-09-04 2014-09-04 Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
SE1550344 2015-03-24
SE1550344-4 2015-03-24
PCT/SE2015/050939 WO2016036308A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3175785A Division CA3175785A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Publications (2)

Publication Number Publication Date
CA2959307A1 CA2959307A1 (en) 2016-03-10
CA2959307C true CA2959307C (en) 2023-03-28

Family

ID=55440194

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2959307A Active CA2959307C (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
CA3175785A Pending CA3175785A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3175785A Pending CA3175785A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Country Status (16)

Country Link
US (5) US10071069B2 (enExample)
EP (3) EP3782617B1 (enExample)
JP (2) JP6622310B2 (enExample)
CN (1) CN107072973A (enExample)
AU (3) AU2015312430B2 (enExample)
CA (2) CA2959307C (enExample)
DK (2) DK3188725T3 (enExample)
ES (2) ES2973289T3 (enExample)
FI (1) FI3782617T3 (enExample)
HR (2) HRP20240314T1 (enExample)
HU (2) HUE052857T2 (enExample)
PL (2) PL3782617T3 (enExample)
PT (2) PT3782617T (enExample)
RS (1) RS65337B1 (enExample)
SI (2) SI3782617T1 (enExample)
WO (1) WO2016036308A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
WO2016083863A1 (en) * 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
SG11201808713YA (en) * 2016-04-11 2018-11-29 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
BR112019001082A2 (pt) * 2016-07-20 2019-04-30 Abbvie Inc. gel intestinal de levodopa e carbidopa e métodos de uso
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
WO2018146194A1 (en) * 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Liquid composition containing pradofloxacin
WO2019129120A1 (en) * 2017-12-28 2019-07-04 Rpxds Co., Ltd Tolcapone for prevention and/or treatment of obesity and related metabolic diseases
AU2019237857B2 (en) * 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
EP3593819A1 (en) 2018-07-10 2020-01-15 Medday Pharmaceuticals Compositions for therapeutic uses containing 5-htp and carbidopa
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
PT3897578T (pt) * 2018-12-18 2025-01-13 Lilly Co Eli Regimes de dosagem para utilização de ly3154207 no tratamento de distúrbios do snc dopaminérgicos
JP7506371B2 (ja) * 2020-01-20 2024-06-26 国立大学法人浜松医科大学 ドーパミン減少抑制剤
CN120478288A (zh) * 2020-03-13 2025-08-15 巴尔-波特拉及康邦亚股份有限公司 微粉化的奥匹卡朋
CN111643493B (zh) * 2020-05-26 2023-01-10 上海京新生物医药有限公司 一种高浓度左旋多巴制剂及其制备方法及其应用
CN116601146A (zh) 2020-10-07 2023-08-15 伊莱利利公司 作为多巴胺d1受体正变构调节剂的苯基-3,4-二氢异喹啉-2(1h)-基-乙-1-酮衍生物
WO2022158991A1 (en) * 2021-01-20 2022-07-28 Bial-Portela & Ca., S.A. Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa
CN117731627B (zh) * 2023-12-20 2026-04-10 重庆迈川医药科技有限公司 一种多巴丝肼片及其制备方法和应用
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004348D0 (en) 1990-02-27 1990-04-25 Orion Yhtymae Oy New use of catechol derivatives and their physiologically acceptable salts and esters
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
JP2002529407A (ja) * 1998-11-10 2002-09-10 テバ ファーマシューティカル インダストリーズ リミティド Ｌ−ｄｏｐａエチルエステル含有分散性組成物
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
JP5160786B2 (ja) 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20060222703A1 (en) 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
AU2009211028B2 (en) * 2008-02-06 2013-12-05 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
RU2559083C9 (ru) * 2009-05-19 2016-01-20 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
US20130253056A1 (en) * 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN110123743A (zh) 2010-11-15 2019-08-16 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
RU2677278C2 (ru) 2013-03-13 2019-01-16 Неуродерм Лтд Способ лечения болезни паркинсона
SE538425C2 (en) 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor

Also Published As

Publication number Publication date
PL3782617T3 (pl) 2024-06-24
PT3782617T (pt) 2024-02-29
HRP20210025T1 (hr) 2021-03-05
US10786472B2 (en) 2020-09-29
JP6889231B2 (ja) 2021-06-18
DK3782617T3 (da) 2024-03-04
EP3782617B1 (en) 2024-01-03
AU2022200291A1 (en) 2022-02-10
EP3188725B1 (en) 2020-10-28
ES2844500T3 (es) 2021-07-22
EP4356907A1 (en) 2024-04-24
RS65337B1 (sr) 2024-04-30
PT3188725T (pt) 2021-01-27
JP2017527623A (ja) 2017-09-21
US10071069B2 (en) 2018-09-11
EP3782617A1 (en) 2021-02-24
US20170231937A1 (en) 2017-08-17
CN107072973A (zh) 2017-08-18
SI3188725T1 (sl) 2021-04-30
US12156858B2 (en) 2024-12-03
US20250041257A1 (en) 2025-02-06
JP6622310B2 (ja) 2019-12-18
HUE052857T2 (hu) 2021-05-28
AU2020239682A1 (en) 2020-10-15
US11413262B2 (en) 2022-08-16
AU2022200291B2 (en) 2024-01-25
FI3782617T3 (fi) 2024-03-13
PL3188725T3 (pl) 2021-08-02
CA3175785A1 (en) 2016-03-10
CA2959307A1 (en) 2016-03-10
HRP20240314T1 (hr) 2024-05-24
US20210023033A1 (en) 2021-01-28
HUE066097T2 (hu) 2024-07-28
EP3188725A1 (en) 2017-07-12
AU2015312430A1 (en) 2017-03-30
JP2020045353A (ja) 2020-03-26
AU2020239682B2 (en) 2021-12-23
SI3782617T1 (sl) 2024-04-30
EP3188725A4 (en) 2018-04-25
DK3188725T3 (da) 2021-01-18
WO2016036308A1 (en) 2016-03-10
ES2973289T3 (es) 2024-06-19
US20180338944A1 (en) 2018-11-29
US20220362193A1 (en) 2022-11-17
AU2015312430B2 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
AU2022200291B2 (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
US10555922B2 (en) Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US20250213518A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
JP2021519272A5 (enExample)
HK40110793A (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
HK40044749A (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone
HK40044749B (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200623

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250826